Roman Hájek

2007–2025 年に発表

別表記
Roman Hajek
199
論文数
29,372
被引用数
81
h 指数
181
i10 指数

被引用数

Roman Hájek の年別被引用数1948 年: 被引用 1 件1988 年: 被引用 1 件2004 年: 被引用 1 件2007 年: 被引用 2 件2008 年: 被引用 9 件2009 年: 被引用 34 件2010 年: 被引用 40 件2011 年: 被引用 75 件2012 年: 被引用 69 件2013 年: 被引用 113 件2014 年: 被引用 162 件2015 年: 被引用 128 件2016 年: 被引用 207 件2017 年: 被引用 230 件2018 年: 被引用 192 件2019 年: 被引用 797 件2020 年: 被引用 986 件2021 年: 被引用 1,359 件2022 年: 被引用 1,091 件2023 年: 被引用 768 件2024 年: 被引用 1,447 件2025 年: 被引用 741 件2026 年: 被引用 15 件1949〜1987 年は被引用が無いため表示していません1989〜2003 年は被引用が無いため表示していません2005〜2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,567 件、この内訳の 23.3%イタリア: 引用元論文 715 件、この内訳の 6.5%中国: 引用元論文 705 件、この内訳の 6.4%ドイツ: 引用元論文 673 件、この内訳の 6.1%イギリス: 引用元論文 592 件、この内訳の 5.4%フランス: 引用元論文 590 件、この内訳の 5.3%スペイン: 引用元論文 553 件、この内訳の 5%カナダ: 引用元論文 393 件、この内訳の 3.6%オランダ: 引用元論文 355 件、この内訳の 3.2%ギリシャ: 引用元論文 340 件、この内訳の 3.1%オーストラリア: 引用元論文 322 件、この内訳の 2.9%日本: 引用元論文 265 件、この内訳の 2.4%
0%23.3%その他 26.8%

分野

  • Medicine79.4%
  • Biochemistry, Genetics and Molecular Biology15.4%
  • Immunology and Microbiology2.4%
  • Chemistry0.6%
  • Materials Science0.4%
  • Engineering0.3%
  • その他1.5%

トピック

  • Multiple Myeloma Research and Treatments16.7%
  • Protein Degradation and Inhibitors7.9%
  • Acute Myeloid Leukemia Research6.3%
  • Peptidase Inhibition and Analysis4.1%
  • CAR-T cell therapy research3.2%
  • Cancer Treatment and Pharmacology2.8%
  • その他59%

共著者

全論文

検索で開く
  1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 2,771

  2. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 被引用: 515

  3. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 820

  4. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 178

  5. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 被引用: 380

  6. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn ほか 30 名 - The Lancet 2019 被引用: 636

  7. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  8. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon McNamara, Xiangdong Zhou, Maureen Nichols, Eric Lewis, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos - New England Journal of Medicine 2024 被引用: 166

  9. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 被引用: 275

  10. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski ほか 69 名 - The Lancet 2018 被引用: 726

  11. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 被引用: 324

  12. TGF-β – an excellent servant but a bad master

    著者: , , , - Journal of Translational Medicine 2012 被引用: 512

  13. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2010 被引用: 876

  14. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 1,324

  15. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 被引用: 762

  16. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 243

  17. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 99

  18. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268

  19. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 被引用: 95

  20. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Surbhi Sidana, Giampaolo Merlini, Tom Martin, Yi Lin, Ajai Chari, Rakesh Popat, Jonathan L. Kaufman - The Lancet Oncology 2024 被引用: 119

  21. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

    著者: , , , , , , , , , , , , - Blood Cancer Journal 2021 被引用: 167

  22. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

    著者: , , , , , , , , , , , - Blood Cancer Journal 2018 被引用: 226

  23. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark‐David Levin, Gerard M.J. Bos, Heinz Ludwig, Sara Aquino, Anna Morelli, Ka Lung Wu, Rinske Boersma, Roman Hájek, Marc Durian, Peter A. von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf‐Henrik Mellqvist, Marinus van Marwijk Kooy, Monique C. Minnema, Caroline M.P.W. Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld - The Lancet Haematology 2020 被引用: 384

  24. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé - British Journal of Haematology 2021 被引用: 174